GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“GLP-1R was further detected in the arterial walls of the kidney and lung, in heart myocytes of the sinoatrial node, and in the Brunner’s gland of the duodenum [392].”
BackgroundInfluentialGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationle Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
“Expression of GLP-1 R (protein level) in intact arterial or venous blood vessels is less certain 11 Angiogenesis, endothelial cell proliferation See table 1 (mostly studied in endothelial cells of human origin) Effects on endothelial cell proliferation and angiogenesis appear likely Endotheliumderived vasodilation (NO…”
BackgroundRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“Similar to findings in the vascular bed, we did not identify GLP-1R expression in the liver (data not shown), concordant with previous reports (38,39,47).”
BackgroundResultSelf-citationPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Long term use of beinaglutide, a recombinant human GLP-1(7-36) acid, was demonstrated to reduce the body weight and improve steatosis (194).”
BackgroundInfluentialFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
“However, the mechanisms are still unclear(121) and likely complex given that GLP-1 receptors are widely distributed across many tissues.(102,113) However, their metabolic and cardiovascular benefit is likely to go beyond that of weight loss alone, as albiglutide (a GLP-1RA that does not induce significant weight loss)…”
BackgroundResultGLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
“Although a study that used the most extensively validated monoclonal antibody for GLP-1R to date showed that GLP-1R was exclusively expressed in the preglomerular vascular smooth muscle cells and juxtaglomerular cells of primate kidneys 106 , uncertainties remain regarding receptor localization.”
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Such a discrepancy between humans and rodentsmay reside on the different expression level of GLP-1R in the thyroid because C cells are very sparse in primates when comparedwith rodents (Gallo, 2013; Pyke et al., 2014).”
BackgroundNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
“(exendin [9-39]) and, more recently, a GIP receptor agonist (GIP [3-30] NH2) and, hopefully, longer-acting GIP receptor agonists for human use will be helpful tools to”
BackgroundCardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
“to the monkey and human sinoatrial node further diminishes the likelihood of a direct GLP-1R–ANP axis in humans.(59)”
BackgroundHausenloy, D. J., Garcia-Dorado, D., Bøtker, H. E., Davidson, S. M., Downey, J., Engel, F. B., Jennings, R., Lecour, S., Leor, J., Madonna, R., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx049 · Cited by 356
“For example, cardiac expression of some receptors can differ between rodents and humans, as for GLP-1R.(120,121)”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
“with the previous detection of GLP-1Rswithin human and nonhuman primate atrial tissue (23), implicates one or more direct roles forGLP-1R signaling in the human heart.”
BackgroundMethodInfluentialReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
“Although the underlying physiological mechanisms have not yet been defined, the activation of the GLP-1 receptors in the sino-atrial node could play a role [77].”
BackgroundPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“Detection of GLP-1R immunopositivity in several VSMs within the preglomerular vascular compartment was corroborated by analysis of matched sections using in situ radiolabeled ligand binding, which identified binding in a blood vessel that also stained positive with Mab 3F52 (44).”
BackgroundMethodResultInfluentialFarr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
“We did not see any changes in fMRI activation of the hypothalamus with liraglutide, in contrast to immunohistochemistry findings in rodents and primates [10, 12].”
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
“in heart rate (2–3 beats/min), which likely is related to the presence of GLP-1 receptors in the SA node.(244) Glucagon-like peptide-1(245) and GLP-1RAs(246,247) also improve endothelial dysfunction in”
BackgroundThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
“There is a dense network of nerve fibres staining positively for the GLP-1 receptor in the intestinal wall [61], andmany cell bodies in”
BackgroundBeyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“GLP1R is expressed in the kidney, localized to a subset of vascular smooth muscle cells (VSMCs) within afferent arterioles 97,98 (Fig.”
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Borghetti, G., von Lewinski, D., Eaton, D. M., Sourij, H., Houser, S. R., & Wallner, M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01514 · Cited by 238
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
“GLP-1 binds to a specific GLP-1 receptor (GLP-1R), which is expressed in various tissues, including pancreatic beta cells, pancreatic ducts, gastric mucosa, kidney, lung, heart, skin, immune cells, and the hypothalamus [26].”
BackgroundChuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“The mechanism for this is currently unknown, but may be mediated by direct actions of these drugs on sinoatrial node [185] or activation of the sympathetic nervous system [186].”
BackgroundIwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
“To examine the involvement of GLP-1R signaling, Ex(9-39) (200 nmol kg−1) or saline was i.”
InfluentialMetabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Heppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
“heart of rodents (87) as well as the NHP and humans (32),”
BackgroundMethodInfluentialSelf-citationIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192
Zhang, Y., Zhou, H., Wu, W., Shi, C., Hu, S., Yin, T., Ma, Q., Han, T., Zhang, Y., Tian, F., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.035 · Cited by 189
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E.-M., Valeur, E., Jansson-Löfmark, R., Janzén, D., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 188
“RESULTS Conjugation of a GLP1R peptide agonist to an ASO GLP1R is a GPCR belonging to the secretin receptor family, with limited human and rodent tissue distribution (15, 16).”
BackgroundGlucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
“Similarly, analysis of monkey liver by immunohistochemistry using the validated Mab 3F52 monoclonal anti-GLP-1R antibody did not detect GLP-1R+ liver cells (76).”
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
“In humans, GLP-1R has been identified in the kidney localized in proximal tubular cells and preglomerular vascular smooth muscle cells [18].”
BackgroundGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
“It is more likely that increased HR results from a direct GLP-1 receptor-mediated effect on the endogenous sinoatrial pacemaker node of the heart, as GLP-1 receptors are expressed in the human heart in myocytes in the sinoatrial node [33].”
BackgroundThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Botfield, H. F., Uldall, M. S., Westgate, C. S. J., Mitchell, J. L., Hagen, S. M., Gonzalez, A. M., Hodson, D. J., Jensen, R. H., & Sinclair, A. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0972 · Cited by 163
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Patel Chavez, C., Cusi, K., & Kadiyala, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 162
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Zhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., Wang, N., & Lu, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00233 · Cited by 153
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“No GLP-1R was seen in primate liver and thyroid [73,74].”
BackgroundLund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
“GLP-1 asserts its effects through binding to the GLP-1Rs expressed in the pancreas and a variety of other tissues including: lung, heart, blood vessels, gastrointestinal tract, kidney, breast and central nervous system (CNS) [15–17].”
BackgroundGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
“GLP-1R have been identified in vascular smooth muscle cells of preglomerular arterioles in human and experimental animal kidneys [61] but cannot be easily detected by immunohistochemistry or imaging, and levels of expression may be below the sensitivity of the techniques [62].”
BackgroundRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“No expression of GLP-1R is found in the liver and the thyroid gland (44).”
BackgroundLambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146
“The chronotropic effect of GLP-1 analogues are believed to be mediated via GLP-1 receptors located to the sinoatrial node [40].”
BackgroundJensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
“With the use of the primate-specific GLP-1R monoclonal antibody (MAb; 3F52) (14), we have previously described the GLP-1R distribution in the nonhuman primate brain (15).”
BackgroundSelf-citationJensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141
Ast, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Koszegi, Z., Bacon, A., Jones, B. J., Lucey, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 140
Sourris, K. C., Ding, Y., Maxwell, S. S., Al-sharea, A., Kantharidis, P., Mohan, M., Rosado, C. J., Penfold, S. A., Haase, C., Xu, Y., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.029 · Cited by 143
Self-citationUssher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 139
“The localization of the GLP-1R to sinoatrial nodal cells in primates [29], raises the possibility that GLP-1R agonists increase HR through direct activation of atrial pacemaker cells.”
BackgroundResultKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Koehler, J. A., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., & Drucker, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.005 · Cited by 133
“, 2014) and primates (Pyke et al., 2014), and FGF7 has been detected in the human ENS, raising the possibility that the ENS communicates a GLP-1R-dependent signal that converges on Fgf7 and ultimately promotes crypt fission.”
BackgroundClinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Chuang, M.-H., Chen, J.-Y., Wang, H.-Y., Jiang, Z.-H., & Wu, V.-C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.27258 · Cited by 133
Obesity and cardiovascular risk
Kotsis, V., Jordan, J., Micić, D., Finer, N., Leitner, D. R., Toplak, H., Tokgözoğlu, L. S., Athyros, V. G., Elisaf, M., Filippatos, T. D., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001730 · Cited by 162
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128
Is GLP‐1 a hormone: Whether and When?
D'Alessio, D. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12466 · Cited by 130
“GLP-1 is cleaved from proglucagon in specific intestinal enterocytes called L cells, and secreted primarily as an amidated 30amino acid peptide GLP-1(7-36)NH2 (1,17).”
BackgroundInfluentialMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective
Jensterle, M., Janez, A., Fliers, E., DeVries, J. H., Vrtacnik-Bokal, E., & Siegelaar, S. E. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz019 · Cited by 128
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
“GLP-1 receptors have been demonstrated in human and monkey smooth muscle cells of the afferent renal arteriole using a validated monoclonal antibody [30].”
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“In the human heart, GLP-1Rs have been localized to the sinoatrial node, where they are thought to accelerate heart rate, which is unlikely to represent a beneficial effect 142 .”
Ackeifi, C., Wang, P., Karakose, E., Manning Fox, J. E., González, B. J., Liu, H., Wilson, J., Swartz, E., Berrouet, C., Li, Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw9996 · Cited by 125
GLP-1 and Amylin in the Treatment of Obesity
Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 125
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Never waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
Baggio, L. L., Ussher, J. R., McLean, B. A., Cao, X., Kabir, M. G., Mulvihill, E. E., Mighiu, A. S., Zhang, H., Ludwig, A., Seeley, R. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.010 · Cited by 117
“The identification of GLP-1R expression in the atria of mice [12,13] and in the sinoatrial node of monkey [14] raised the additional possibility that GLP-1 may also modulate HR via a direct effect through the cardiac GLP1R.”
BackgroundInfluentialGalsgaard, K. D., Winther-Sørensen, M., Ørskov, C., Kissow, H., Poulsen, S. S., Vilstrup, H., Prehn, C., Adamski, J., Jepsen, S. L., Hartmann, B., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00198.2017 · Cited by 115
Self-citationDavies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
“Preliminary data indicate the presence of GLP-1 receptors on the sino-atrial node in nonhuman primates and humans, suggesting a direct chronotropic effect of liraglutide.(17) Limitations of this analysis include the wide confidence intervals and the retrospective adjudication of events in 2 of the trials.”
BackgroundGLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113
Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112
“This antibody has been extensively validated to show its specificity [13, 14].”
BackgroundGLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“GLP-1 receptors are widely expressed in many tissues beyond the pancreas, including the gastrointestinal system, cardiovascular system, central nervous system and kidneys (15,38,39).”
BackgroundInfluentialGLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
“After cutting, the tissue was stained with DAPI together with staining for the GLP-1R with an in-house generated mouse antihuman MAb (3F52) directed against GLP-1R extracellular domain.(28)”
MethodSelf-citationDo we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
“In addition, numerous neurons of the enteric nervous system express a high density of GLP-1 receptors.(28) Administration of GLP-1 increased vagal afferent activity in rats via a receptor-dependent mechanism (effect blocked by concurrent administration of exendin 9-39),(29)”
BackgroundSelective tissue targeting of synthetic nucleic acid drugs
Seth, P. P., Tanowitz, M., & Bennett, C. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125228 · Cited by 109
“Glucagon-like peptide 1 receptor (GLP1R) is a secretin-like, class B GPCR primarily expressed in pancreatic β cells, with limited expression in other tissues such as the brain and gut (95, 96).”
BackgroundGLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
“GLP1-Rs consist of 463 amino acids and are expressed in pancreatic islet cells, as well as in other organs, such as the gastrointestinal tract, lung, heart, kidney and brain, exerting indirect metabolic actions [30].”
BackgroundWang, Y., Jin, M., Cheng, C. K., & Li, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238927 · Cited by 151
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 130
Jara, M., Norlin, J., Kjær, M. S., Almholt, K., Bendtsen, K. M., Bugianesi, E., Cusi, K. J., Galsgaard, E. D., Geybels, M. S., Gluud, L. L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03799-0 · Cited by 115
“GLP-1 receptor expression was assessed in human liver biopsies as described previously 42,43 with some modifications.”
Self-citationDoes Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?
Magruder, M. L., Yao, V. J. H., Rodriguez, A. N., Ng, M. K., Sasson, V., & Erez, O. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.05.071 · Cited by 106
The effect of liraglutide on renal function: A randomized clinical trial
von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12808 · Cited by 105
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.043 · Cited by 104
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.